Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer

Oncologist

Volumn 17, Issue 11, 2012, Pages 1426-1428

  Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; ENZASTAURIN; FLUOROPYRIMIDINE; PLACEBO; VASCULOTROPIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; DRUG COST; HUMAN; MAINTENANCE THERAPY; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; ANTIANGIOGENIC THERAPY; DISEASE COURSE; DRUG WITHDRAWAL; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; LEUCOVORIN; MAINTENANCE CHEMOTHERAPY; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84869406393     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0075     Document Type: Article

References (12)

1. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicenter randomized trial. Lancet 2003;361:457-464.
2. Chibaudel B, Maindrault-Goebel F, Mineur L et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-5733.
3. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642-653.
4. Labianca R, Sobrero A, Isla I et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: A randomized GISCAD trial. Ann Oncol 2011;22: 1236-1242.
5. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. A GERCOR study. J Clin Oncol 2006;24:394-400.
6. Grothey A, Hart L, Rowland K et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 2008;26(15 suppl):4010.
7. Diaz-Rubio E, Gomez-España A, Massuti B et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer (mCRC): The phase III MACRO TTD study. The Oncologist 2012;17:15-25.
8. Grothey A, Sugrue MM, PurdieDMet al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRITE). J Clin Oncol 2008;26:5326-5334.
9. Arnold D, Andre T, Bennouna J et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with BEV + CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012;30(suppl 18):CRA3503.
10. Tabernero J, Van Cutsem E, Lakomy R et al. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. Eur J Cancer 2011; 47(suppl 2):5.
11. Grothey A, Sobrero AF, Siena S et al. Results of a phase III randomized, doubleblind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer who have progressed after standard therapies. J Clin Oncol 2012;30(suppl 4):LBA385.
12. Clinicaltrials.gov. Optimal maintenance therapy with Bevacizumab after induction in metastatic colorectal cancer (CRC). Clinicaltrials.gov identifier NCT00973609. Available at http://clinicaltrials.gov/ct2/show/NCT00973609?term_ML21768&rank_1,accessed October 5, 2012.